A single-arm extension study to investigate the long-term safety, tolerability, and efficacy of lunsekimig in adult participants with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) who completed a previous lunsekimig CRSwNP clinical study

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515912-27-00

Acronym

LTS18300

Enrollment

Registered

2025-06-11

Start date

2025-12-08

Completion date

Unknown

Last updated

2025-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic rhinosinusitis with nasal polyps

Brief summary

Incidence of participants with treatment-emergent adverse events (TEAEs) including adverse events of special interest (AESI), and serious adverse events (SAEs)

Detailed description

Change in SNOT-22 total score, Change in rhinosinusitis visual analog scale (VAS), Change in University of Pennsylvania Smell Identification Test (UPSIT) score, Serum lunsekimig concentrations, Anti-drug antibodies (ADA) against lunsekimig

Interventions

DRUGSAR443765 / LUNSEKIMIG

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence of participants with treatment-emergent adverse events (TEAEs) including adverse events of special interest (AESI), and serious adverse events (SAEs)	—

Secondary

Measure	Time frame
Change in SNOT-22 total score, Change in rhinosinusitis visual analog scale (VAS), Change in University of Pennsylvania Smell Identification Test (UPSIT) score, Serum lunsekimig concentrations, Anti-drug antibodies (ADA) against lunsekimig	—

Countries

Belgium, Bulgaria, Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026